This transgenic hamster infection model supports TfR1-mediated entry as an essential step in JUNV pathogenesis and provides a novel small-animal model to advance the development of promising host receptor-directed therapies and direct-acting antivirals to improve outcomes in patients with severe disease caused by pathogenic NWMs. This evidence concerns the gene TFRC and infection.